| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Virology and Immunology, German Primate Center, Goettingen, Germany;
Institut für Medizinische Informatik und Statistik, Christian-Albrechts-Universität Kiel, Kiel, Germany; and
Department of Virology and Animal Science, Biomedical Primate Research Center, Rijswijk, The Netherlands
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Potentially, such genetically similar animals could be produced by assisted reproductive technology (2). However, at the moment there are no capacities for a fast large-scale production of such animals in most primate centers. Currently, it would be more feasible to select animals before the onset of an experiment according to predictive genetic properties. Especially the knowledge of genetic markers would allow a routine screening of large numbers of animals and would also facilitate conventional as well as assisted breeding strategies.
In addition, a preclinical animal disease model, relevant for humans, should mimic to some extent the genetic variety in humans. Ideally, this genetic diversity should not be a black box, but should be investigated and manageable. A prerequisite is obviously a knowledge of either the genes influencing the disease course or linked marker sequences. In this respect, the polymorphic Mhc genes are particular valuable, since they play a crucial role during the initiation and regulation of an immune response. Numerous reports on the association of Mhc genes with disease progression in HIV-1-infected humans have been published. Some associations have been repeatedly detected, e.g., HLA-B*14, -B*27, and -B*57 in slow progressors and HLA-B*22, HLA-B*35, and HLA-B*44 in humans with shorter survival time (3, 4, 5, 6, 7, 8, 9, 10). Some of these alleles might also influence cytotoxic T cell responses to vaccines (11). Extended MHC haplotypes which include TAP genes and chemokine coreceptor genes are also known to influence disease progression in HIV-1-infected humans (4, 6, 12, 13, 14) Furthermore, heterozygosity or the presence of MHC molecules able to present many different HIV-1-derived peptides positively influence the disease course in HIV-1-infected humans (7, 15, 16).
Mhc genes and haplotypes associated with disease progression have also been identified in SIV-infected rhesus monkeys (17, 18, 19). Since the virus strains used for most experiments in SIV research are genetically less divers than the different HIV-1 subtypes, one would expect more consistent associations between Mhc alleles and disease progression than in HIV-1-infected humans.
A major obstacle in determining the role of Mhc class I polymorphisms for disease progression in SIV-infected rhesus monkeys is the lack of molecular typing techniques for class I molecules. This reflects a lack of detailed knowledge about the MHC class I region in rhesus macaques. So far, molecular typing techniques have been described only for a few MHC class I molecules (20, 21, 22). In addition, there are remarkable differences between the organization of the human and the macaque Mhc class I region. In contrast to humans, rhesus macaques may possess one to three A and two to four B locus genes (Refs. 23, 24 ; unpublished results). One of the classical B genes seems to be highly conserved and was termed Mamu-I (25). The presence of multiple class I genes may be common to all members of the subtribe Papionina, but their biological significance is unknown (23, 26, 27).
The aim of this study was to identify Mhc class I alleles in rhesus macaques, to develop Mhc class I typing techniques for novel and published alleles, and to identify Mhc class I alleles associated with disease progression in SIV-infected macaques. The results can be used to improve the design and the interpretation of experiments performed in rhesus monkeys.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Samples were collected from 91 naive SIV-infected animals housed at the German Primate Center according to the German animal protection act. Data from most of the animals had been previously published (19, 28, 29, 30, 31, 32). Thirty-seven animals were infected with SIVmac 251 grown on monkey PBMCs (33, 34). Ten monkeys were infected with SIVmac 251/32H grown on the human T cell line C8166 (35). Thirteen rhesus monkeys were infected with the ex vivo isolate SIVmac251/32H/spl (36).
Twenty-nine monkeys were infected with SIVmac239 grown on rhesus monkey PBMCs (37, 38, 39). Two animals were infected with supernatant from SIVmac239-transfected COS cells (40). Forty monkeys were obtained from the German Primate Center breeding colony, originally derived from the Caribbean Primate Research Center colony, Cayo Santiago (Puerto Rico), 15 directly from the Carribbean Primate Research Center, and 36 from Laboratory Animal Breeders and Services of Virginia.
Nucleic acid extraction and synthesis of Mhc class I A and B locus-specific PCR products
DNA was extracted by standard salting-out techniques using
either B cells, lymphocytes, or frozen tissue samples. RNA was
extracted from 2 x 106 –2 x
107 B cells or PBMC using the RNeasy Midi-Kit
(Qiagen, Hilden, Germany). For reverse transcription, 4 µg of total
RNA, 2 µg of random hexamers (Invitrogen, Carlsbad, CA), and a
suitable volume of distilled H2O were incubated
at 70°C for 10 min. Forty units of RNasin (Promega, Mannheim,
Germany), 1 mM dNTP, 10 mM DTT, 1x first-strand buffer (250 mM
Tris-HCl, 375 mM KCl, 15 mM MgCl2), and 600 U of
Superscript II RNase H- reverse transcriptase
(Invitrogen) were added to give a final volume of 40 µl. cDNA was
synthesized at room temperature for 10 min, at 42°C for 30 min, and
at 70°C for 10 min. cDNA was purified and concentrated by
phenol-chloroform extraction and a subsequent ethanol precipitation.
The 50-µl PCR mixture contained 1/10 volume of the purified cDNA, 20
pmol of MHC class I A-(A-DGGE-for and rev) or
B-specific denaturing gradient gel electrophoresis
(DGGE)3 (B-DGGE-for and
rev) primers (Table I
), 200
µM of each deoxyribonucleotide triphosphate (Peqlab, Erlangen,
Germany), 1x PCR buffer, 0.5 M GC-rich resolution solution, and 1 U of
GC-Rich-PCR System Enzyme Mix (Roche Diagnostics, Mannheim, Germany).
The reactions were denatured initially at 95°C for 3 min followed by
30 cycles of 95°C for 30 s, 60°C (A-DGGE primer) or 62°C
(B-DGGE primer) for 30 s, 72°C for 40 s, and a single final
extension step at 72°C for 3 min. Primers used were synthesized and
HPLC purified by Sigma-ARK (Darmstadt, Germany).
|
Thirty microliters of the PCR products were mixed with 15 µl
of loading buffer and separated by electrophoresis in a 10% (37.5:1
acrylamide:bisacrylamide; Bio-Rad, Munich, Germany) polyacrylamide gel
with an increasing gradient of 50–65% denaturant (100%: 7 M urea,
40% formamide; Bio-Rad D-Gene apparatus, Bio-Rad). DGGE analysis was
performed at 130 V and 56°C for 9 h in 1x Tris-acetate-EDTA
buffer. After the run, bands were visualized with SYBR-Green (Biozym,
Hess. Oldendorf, Germany) and excised with sterile scalpels. DNA was
eluted overnight in 50 µl of distilled water at room temperature.
Five microliters of the eluate was mixed with 15 pmol of sequencing
primers (MWG Biotec, Munich, Germany; see Table I
) in a 50-µl
reaction volume containing 200 µM dNTP (Peqlab), PCR buffer and 1 U
GC-Rich-PCR System Enzyme Mix (Roche Diagnostics). The DNA was
denatured initially for 3 min at 95°C. Amplification was performed
for 30 cycles at 95°C for 30 s, at 60°C (A-Seq) or
62°C (B-Seq) for 30 s, and at 72°C for 30 s,
followed by a final elongation step at 72°C for 3 min. PCR products
were purified on spin columns (Millipore, Eschborn, Germany) and
sequenced by SeqLab (Goettingen, Germany) using standard M13 forward
and reverse primers. The DNA sequences described in this article have
been submitted to GenBank and have been assigned the following
accession numbers: NA4, AF518412, NA7, AF519897, NB2, AF519898, NB4,
AF519899, NB5, and AF519900. For registration, the DNA sequences have
been sent to the Primate MHC register, but have not yet been
registered. The designations are therefore arbitrary.
Typing techniques
Thirteen rhesus monkey allele-specific primer pairs (18–22 mer)
were designed based on the published and the novel DNA sequences. The
specific primers for amplification of the Mhc class I
A and B locus alleles are listed in Table I.
Allele-specific PCR products ranged in size from 408 to 
1300 bp. MHC
DRB gene-specific primers (MDRB5' and
3'MDR) served as an internal control (20).
Primers were synthesized and purified by a high-purity salt-free method
(HPSF) from MWG Biotec. A reaction mixture of 25 µl contained 70–110
ng DNA, PCR buffer, Q-solution, 200 µM dNTP, 15–20 pmol
allele-specific 5' and 3' primer, 2–10 pmol of the DRB primers, and
1.25 U of Taq polymerase (Qiagen). The samples were
denatured initially at 95°C for 3 min followed by 30–37 cycles at
95°C for 30 s, 58–63°C for 40 s, 72°C for
40 s, and a final elongation step at 72°C for 3 min (Table II). Allele-specific products were
identified by electrophoresis of amplicons in 1% agarose gels
containing ethidium bromide. For the preparation of the sequencing
samples, the PCR was performed as described above, except for the
omission of the internal control primers. Before sequencing, the PCR
samples were directly purified on spin columns (Microcon-PCR;
Millipore) or extracted from an agarose gel electrophoresis using
centrifugal filters (Ultrafree-DA; Millipore). DNA sequencing was
performed by SeqLab using standard M13 forward and M13 reverse
primers.
|
A highly sensitive, single-state QC RT-PCR technique has been developed and validated for the quantification of SIVmac/sm RNA in plasma (41). The sensitivity and dynamic range of this assay are such that it is capable of detecting 40 copies to 4 x 108 copies of SIV RNA per ml of plasma. In brief, RNA is extracted from 200 µl of serum or EDTA plasma using guanidine isothiocyanate-mediated lysis, followed by propanol-2 precipitation of the RNA. A known amount of synthetic internal standard RNA is added before the RNA purification and is copurified to monitor the efficiency of the purification. The RNA is reverse transcribed and amplified in a single reaction protocol using rTth DNA polymerase (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) and biotinylated primers. The internal standard RNA is coamplified to monitor the amplification efficiency. The amplified fragments are detected by a capture probe that is covalently bound to Nucleolink microwells (Nunc, Roskilde, Denmark). The amplification products are detected by a streptavidin-HRP-mediated colorimetric reaction. The amplified internal standard is hybridized to a different capture probe in separate microwells. The number of RNA copies in the sample is calculated from the OD of the sample wells compared with that of the corresponding internal standard well.
Statistical analysis
Contingency tables were tested for a statistically
significant dependence between rows and columns using either Fisher’s
exact test or a 
2 test, depending upon cell
counts. Means of viral load associated with different allelotypes were
compared using a nonparametric Kruskal-Wallis test with
2 approximation. Kaplan-Meier survival
analysis of animals with different allelotypes was performed using a
log rank statistic for comparative purposes and log linear model
fitting for parameter estimation. All statistical analyses were
performed using the SAS software package (SAS version 6; SAS,
Cary, NC).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Initial typing studies using DGGE and DNA sequence determination
of class I-derived RT-PCR products from 14 rhesus macaques led to the
identification of 5 novel class I alleles (Fig. 1). Subsequently, 15 primer pairs were
developed to type the novel and previously published rhesus macaque
class I alleles. The monkeys were also screened for
Mamu-A*01 and Mamu-A*02 (20, 22). The
use of primers specific for Mamu-B*03 or
Mamu-B*04 did not reveal any positive animal in this cohort
(data not shown). Testing of the specificity of the primers by PCR was
mainly performed in another monkey cohort (To Mühl, manuscript in
preparation).
|
Three to nine class I alleles were detected per animal. Table III shows the allele frequencies in the
cohort of 91 unvaccinated monkeys with respect to their origin. As
expected, the allele frequencies differed considerably. Some alleles
were present in 50–80% of all animals, whereas others were present in
only a few animals. Especially, NA7 may be an allele of a
highly conserved gene present in nearly every rhesus monkey of Indian
origin. This allele and highly similar alleles were also detected in
macaques of Chinese origin (data not shown). Recently, a highly
conserved B gene termed Mamu-I has been described
(25). NA7 may be an equivalent of a highly
conserved A gene.
|
Association of MHC class I alleles with viral load and survival time
Two parameters were used to identify rhesus macaque
Mhc class I alleles associated with disease progression:
set-point plasma viral RNA load and survival time after infection. As
viral set-point, either week 20 after infection was used or the time of
death when the monkeys died earlier. A total of 51 animals that died of
AIDS had viral load data available. Among these, a highly significant
negative correlation was observed between survival time and plasma
viral RNA load (Spearman rank correlation coefficient,
r = -0.508, p = 0.004; Fig. 2).
|
2 = 7.3487;
p = 0.0067), NB2 (2
= 4.0809; p = 0.0434), and NB5
(2 = 6.2770; p = 0.0122).
Carriers of one of the three alleles have a lower mean rank and,
therefore, a lower viral load. However, as noted above,
Mamu-A*01 and NB5 are strongly associated. Only
NB2 was not associated with either of the other two
alleles.
When all 91 animals were assessed in a Kaplan-Meier analysis, four
alleles exhibited a statistically significant influence on the survival
time, namely, Mamu-A*01, Mamu-A*08,
Mamu-A*1303, and NB5. These alleles had negative
log ranks associated with them, indicating that they delayed the onset
of symptoms. This is also reflected by
the estimates of the mean survival time (Table IV and Fig. 3).
|
|
2 test was performed to assess whether the
factor belonging to a given allele is significantly different from zero
("no effect"). NB5 and Mamu-A*08 are not
significant predictors of survival time if Mamu-A*01 and
Mamu-A*1303 are also taken in account, but not vice versa.
In summary, the only two independent alleles associated with longer
survival detected are Mamu-A*01 and Mamu-A*1303.
The alleles NB5 or Mamu-A*08 linked to them have
no measurable effect. We next assessed whether the protective effects of Mamu-A*01 and Mamu-A*1303 showed a dosage effect. To this end, carriers of either allele were further distinguished according to whether or not they also carried the other allele or any of NB2, Mamu-B*17, or Mamu-A*11. NB2 was included because carriers had a significantly lower viral load; therefore, NB2 may have a protective effect. Mamu-B*17 and Mamu-A*11 were included because the presence of these alleles had distinguished rapid from slow progressors in a previous study (18, 42). In this study, the number of Mamu-B*17 carriers was too small to detect a significant effect. It should be noted that the five carriers of Mamu-B*17 had a mean survival of 66 wk postinfection (wpi). Two of them were sacrificed at weeks 57 or 70 postinfection with symptoms of AIDS. The other three animals were euthanized before the onset of clinical AIDS at week 25, 79, or 100. Mamu-A*11 was detected only in two slowly progressing animals.
The eight monkeys carrying Mamu-A*01 alone had a mean
survival time of 70.3 ± 8.4 wpi. The five
Mamu-A*01-positive animals with one or more of the putative
protective class I alleles were all censored because they were either
euthanized without AIDS or are still alive. However, three of them were
characterized by a particularly long symptom-free survival time
(censored after 104, 110, and 360 wk, while two of them are still
alive). The difference between these two groups was statistically
significant (log rank 2 = 4.1098, 1
df, p = 0.043). A similar effect was
observed for Mamu-A*1303. Two of the carriers of
Mamu-A*1303 alone had very early onset of AIDS at 14 wpi.
However, the difference between single and multiple carriers failed to
reach statistical significance (log rank 2 =
2.9621, 1 df, p = 0.085). It should be noted
that the two long-term nonprogressors had Mamu-A*01 and
Mamu-A*1303, whereas the third animal with both alleles was
euthanized at 18 wpi without symptoms.
Figure 4 summarizes the results of this
study. Fifty percent of the animals that did not carry either
Mamu-A*01 or Mamu-A*1303, Mamu-B*17,
Mamu-A*11, or NB2 were euthanized within 30 wk
after infection with symptoms of clinical AIDS. In contrast, survival
probability increased with the numbers of alleles considered to protect
against a fast disease course. When the survival times of the animals
that did not carry one of the "protective" alleles were stratified
by the infecting virus, no significant difference was detected between
the cohorts (p = 0.64, log rank test),
excluding any effects due to potential differences in the pathogenicity
of the infecting virus.
|
Mamu-A*1303 belongs to an allelic lineage with members
differing from each other by only a very few amino acids. Variants of
Mamu-A*13 were detected in reasonable frequencies
in the monkey cohort described here. The most frequent variant was
Mamu-A*1302 not associated with longer survival. Therefore,
we analyzed whether the amino acid exchanges occurred in the putative
peptide binding pockets. Mamu-A*1303 and Mamu-A*01 share the same amino
acids in the pockets accommodating peptide positions P1, P2, and P3.
The pockets B and C which bind peptide positions P2 and P3 contribute
the most to the peptide binding specificity of Mamu-A*01
(43). Interestingly, Mamu-A*1303 is distinguished from the
other members of the A*13 lineage in the pocket B
accommodating P2 (Table V). At position 70, Mamu-A*1303 possesses a
glutamic acid residue like Mamu-A*01, whereas the other A*13 variants
contain alanine in this position. This amino acid exchange probably
alters the peptide binding specificity. Mamu-A*1303 differs by a few
residues from Mamu-A*01, however, in pockets D, E, and F accommodating
peptide positions P4, P7, and P9. Thus, one could speculate that
Mamu-A*01 and Mamu-A*1303 present partially overlapping, but not
identical peptide epitopes. Since the residues in contact with the TCR
are different, a larger and more diverse pool of CTLs may be stimulated
when both molecules are present. Interestingly, the pockets
accommodating peptide positions P2 and P3 are also identical in
Mamu-A*03. Albeit it is tempting to extrapolate from amino acid
sequence similarities to peptide binding properties, it should be noted
that the amino acid residues of NA4 putatively involved in peptide
binding are identical to Mamu-A*1303. However, NA4 is not
positively associated with disease progression. The reasons are unknown
but could be related to differences in the cell surface expression
level.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Using the 15 primer pairs, at least 21 different class I alleles were detected in a cohort of 91 monkeys. It is likely that several Mhc alleles still remain undetected since not all PCR products have been sequenced. Using the same PCR conditions in macaques of Chinese origin, another 40 Mhc class I alleles have been identified by subsequent DNA sequence determination (data not shown). Since up to nine class I alleles were detected per monkey, the technique described here allows some insight into the genetic diversity of the class I genes of rhesus macaques. Thus, it represents a further step toward a more sophisticated Mhc class I typing technology for rhesus macaques.
For a few alleles, frequencies have also been studied by other groups.
Mamu-A*08 was found, for example, in 8 (32%) of 25 macaques
(24). The average allele frequency detected here was 48%.
The frequency of Mamu-B*07 was 50%, whereas
in our monkey cohorts the frequency was 28%. The frequency of the
A*13 variants was 40% which is in the same range as
detected here. The frequency of Mamu-A*02 has been reported
to be 18–28% depending on the monkey cohort (22). Thus,
our results are within the expected range of genetic variability among
rhesus macaques of Indian origin.
The relation of single alleles to the disease course of SIV-infected monkeys showed that the only class I allele influencing disease progression robustly was Mamu-A*01. It was significantly associated with lower set-point viral load and longer survival time. The other alleles with significant prognostic potential were Mamu-A*1303 in terms of survival time and NB2 with respect to viral load. In addition, increasing numbers of these alleles are associated with prolonged survival time. About 50% of the monkeys with none of these alleles or Mamu-B*17 died within 30 wpi with symptoms of AIDS. This indicates that we probably have identified the most frequent Mhc class I alleles positively influencing disease course in these animals.
To date, Mamu-A*01 is the best studied rhesus macaque class I molecule. It seems to elicit an immunodominant CTL response in the acute as well as in the chronic phase of infection (44). Furthermore, a recent report has shown that Mamu-A*01 may positively influence the results of vaccine studies (45). Detailed analysis of the SIV-specific immune response elicited by Mamu-A*1303 especially with respect to the variants containing an amino acid exchange at position 70 and NB2 will have to be performed.
Mamu-A*01 was linked to NB5 and Mamu-A*1303 was strongly linked to Mamu-A*08. Although, statistically, neither NB5 nor Mamu-A*08 are associated with disease progression, they may present SIV peptides and a positive effect cannot be excluded completely. It is worthy of note that SIV-derived peptide epitopes have been reported for Mamu-A*02, and Mamu-A*08 (22, 46). However, we did not detect any significant positive associations of these alleles with disease progression although they were present in reasonable frequencies. Thirty percent of the Mamu-A*02 carriers had to be euthanized within 28 wpi due to clinical symptoms of AIDS. The presence of Mamu-A*02 was verified by DNA sequence analysis. Since we have recently described an Mhc class II genotype associated with rapid disease progression, we analyzed whether the Mamu-A*08 or Mamu-A*02 was present in higher frequencies in the animals possessing this genotype, and thus whether a linkage effect accounted for the lack of positive influence on the disease course. Fifteen of 31 animals euthanized with AIDS-related symptoms within 30 wpi possessed the Mhc class II-encoded putative rapid progressor genotypes (homozygosity for Mamu-DQB1*0601, DRB1*309, DRB*W201 or Mamu-DQB1*1806, *0601, DRB1*0406, DRB5*0301, DRB1*309, DRB*W201) (19). Mamu-A*02 was absent in all 15 animals carrying one of these genotypes. The frequency of Mamu-A*08 was 27% in these animals and thus met the expectations. Therefore, any effect due to an overrepresentation of these alleles in animals with putatively unfavorable Mhc class II alleles can be excluded.
The CTL responses directed against peptides presented by Mamu-A*02 were
detected in animals with a chronic infection status (22).
According to our data, it seems plausible that these animals carried
other Mhc class I alleles associated with longer survival.
Vigorous CTL responses triggered by other class I molecules may have
helped to contain the virus, to reduce the appearance of escape
mutants, or to induce the enhanced expression of the
Mamu-A*02 by IFN-
and other Th1-related cytokines so that
immune responses mediated by Mamu-A*02 were measurable.
The next issue to be addressed is whether the previously described Mhc class II-encoded "rapid progressor genotype" could be explained by a linkage effect. These class II genotypes were linked to several distinct class I haplotypes. However, except for one rapid progressing animal with Mamu-A*1303, none of these animals carried any of the alleles associated with longer survival. Thus, whether the described Mhc class II genotypes exert a negative influence on the disease course is unclear. To date, we are aware of only two animals with this genotype which survived for longer. We hypothesized earlier that the presence of a class I molecule able to sustain strong SIV-specific CTL responses may prevent rapid disease progression in these animals. One animal (8482; Ref. 19) carried Mamu-A*1303 and Mamu-B*17, whereas the other animal carried Mamu-A*01, NB2, and a rare allele similar to Mamu-A*11, supporting this suggestion. Unfortunately, there were no other animals with similar class I allele combinations but different Mhc class II alleles that could be used for comparison. However, the predictive value of this Mhc class II genotype in rhesus macaques originating from the Caribbean Primate Research Center is probably close to 100%.
In conclusion, the results demonstrate that Mhc class I genes exert a major influence on disease progression in SIV-infected macaques. Mhc typing can thus be used to predict the disease course. Animals likely to develop a disease course representing one of the extremes of disease variability, namely, rapid progression or long-term survival, can be identified before the onset of an experiment. Allocating untyped animals in small numbers to treated and control groups may severely confound the results of AIDS vaccine trials or treatment trials in rhesus monkeys. Given these implications, the results described here can contribute to a significant improvement of such experiments, and the studies should therefore be extended. In addition, non-MHC genes influencing viral containment must also be identified to improve the understanding and the quality of preclinical studies in rhesus monkeys.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Ulrike Sauermann, Department of Virology and Immunology, German Primate Center, Kellnerweg 4, D-37077 Goettingen, Germany. E-mail address: usauerm{at}dpz.gwdg.de
3 Abbreviations used in this paper: DGGE, denaturing gradient gel electrophoresis; wpi, week postinfection.
Received for publication March 28, 2002. Accepted for publication July 12, 2002.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  M. Kubo, Y. Nishimura, M. Shingai, W. Lee, J. Brenchley, B. Lafont, A. Buckler-White, T. Igarashi, and M. A. Martin Initiation of Antiretroviral Therapy 48 Hours after Infection with Simian Immunodeficiency Virus Potently Suppresses Acute-Phase Viremia and Blocks the Massive Loss of Memory CD4+ T Cells but Fails To Prevent Disease J. Virol., July 15, 2009; 83(14): 7099 - 7108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Burwitz, C. J. Pendley, J. M. Greene, A. M. Detmer, J. J. Lhost, J. A. Karl, S. M. Piaskowski, R. A. Rudersdorf, L. T. Wallace, B. N. Bimber, et al. Mauritian Cynomolgus Macaques Share Two Exceptionally Common Major Histocompatibility Complex Class I Alleles That Restrict Simian Immunodeficiency Virus-Specific CD8+ T Cells J. Virol., June 15, 2009; 83(12): 6011 - 6019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Zahn, M. D. Rett, B. Korioth-Schmitz, Y. Sun, A. P. Buzby, S. Goldstein, C. R. Brown, R. A. Byrum, G. J. Freeman, N. L. Letvin, et al. Simian Immunodeficiency Virus (SIV)-Specific CD8+ T-Cell Responses in Vervet African Green Monkeys Chronically Infected with SIVagm J. Virol., December 1, 2008; 82(23): 11577 - 11588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Genesca, P. J. Skinner, J. J. Hong, J. Li, D. Lu, M. B. McChesney, and C. J. Miller With Minimal Systemic T-Cell Expansion, CD8+ T Cells Mediate Protection of Rhesus Macaques Immunized with Attenuated Simian-Human Immunodeficiency Virus SHIV89.6 from Vaginal Challenge with Simian Immunodeficiency Virus J. Virol., November 15, 2008; 82(22): 11181 - 11196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Rogers, L. Jayashankar, F. Scinicariello, and R. Attanasio Nonhuman Primate IgA: Genetic Heterogeneity and Interactions with CD89 J. Immunol., April 1, 2008; 180(7): 4816 - 4824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Butler, A. Theodossis, A. I. Webb, M. A. Dunstone, R. Nastovska, S. H. Ramarathinam, J. Rossjohn, A. W. Purcell, and S. Perlman Structural and Biological Basis of CTL Escape in Coronavirus-Infected Mice J. Immunol., March 15, 2008; 180(6): 3926 - 3937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Loffredo, A. T. Bean, D. R. Beal, E. J. Leon, G. E. May, S. M. Piaskowski, J. R. Furlott, J. Reed, S. K. Musani, E. G. Rakasz, et al. Patterns of CD8+ Immunodominance May Influence the Ability of Mamu-B*08-Positive Macaques To Naturally Control Simian Immunodeficiency Virus SIVmac239 Replication J. Virol., February 15, 2008; 82(4): 1723 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Loffredo, J. Maxwell, Y. Qi, C. E. Glidden, G. J. Borchardt, T. Soma, A. T. Bean, D. R. Beal, N. A. Wilson, W. M. Rehrauer, et al. Mamu-B*08-Positive Macaques Control Simian Immunodeficiency Virus Replication J. Virol., August 15, 2007; 81(16): 8827 - 8832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Loffredo, B. J. Burwitz, E. G. Rakasz, S. P. Spencer, J. J. Stephany, J. P. Giraldo Vela, S. R. Martin, J. Reed, S. M. Piaskowski, J. Furlott, et al. The Antiviral Efficacy of Simian Immunodeficiency Virus-Specific CD8+ T Cells Is Unrelated to Epitope Specificity and Is Abrogated by Viral Escape J. Virol., March 15, 2007; 81(6): 2624 - 2634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Chu, Z. Lou, Y. W. Chen, Y. Liu, B. Gao, L. Zong, A. H. Khan, J. I. Bell, Z. Rao, and G. F. Gao First Glimpse of the Peptide Presentation by Rhesus Macaque MHC Class I: Crystal Structures of Mamu-A*01 Complexed with Two Immunogenic SIV Epitopes and Insights into CTL Escape J. Immunol., January 15, 2007; 178(2): 944 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. Yeh, E. M. Cale, P. Jaru-Ampornpan, C. I. Lord, F. W. Peyerl, and N. L. Letvin Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with gag epitope cytotoxic T-lymphocyte escape mutations. J. Virol., August 1, 2006; 80(16): 8168 - 8177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Yant, T. C. Friedrich, R. C. Johnson, G. E. May, N. J. Maness, A. M. Enz, J. D. Lifson, D. H. O'Connor, M. Carrington, and D. I. Watkins The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B*17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication. J. Virol., May 1, 2006; 80(10): 5074 - 5077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Fogg, D. Garry, A. Awad, F. Wang, and A. Kaur The BZLF1 Homolog of an Epstein-Barr-Related {gamma}-Herpesvirus Is a Frequent Target of the CTL Response in Persistently Infected Rhesus Macaques J. Immunol., March 15, 2006; 176(6): 3391 - 3401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Barratt-Boyes, A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors J. Gen. Virol., January 1, 2006; 87(1): 139 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Newberg, K. J. McEvers, D. A. Gorgone, M. A. Lifton, S. H. C. Baumeister, R. S. Veazey, J. E. Schmitz, and N. L. Letvin Immunodomination in the Evolution of Dominant Epitope-Specific CD8+ T Lymphocyte Responses in Simian Immunodeficiency Virus-Infected Rhesus Monkeys J. Immunol., January 1, 2006; 176(1): 319 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. McDermott, D. H. O'Connor, S. Fuenger, S. Piaskowski, S. Martin, J. Loffredo, M. Reynolds, J. Reed, J. Furlott, T. Jacoby, et al. Cytotoxic T-Lymphocyte Escape Does Not Always Explain the Transient Control of Simian Immunodeficiency Virus SIVmac239 Viremia in Adenovirus-Boosted and DNA-Primed Mamu-A*01-Positive Rhesus Macaques J. Virol., December 15, 2005; 79(24): 15556 - 15566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mao, B. A. P. Lafont, T. Igarashi, Y. Nishimura, C. Brown, V. Hirsch, A. Buckler-White, R. Sadjadpour, and M. A. Martin CD8+ and CD20+ Lymphocytes Cooperate To Control Acute Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys: Modulation by Major Histocompatibility Complex Genotype J. Virol., December 1, 2005; 79(23): 14887 - 14898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Krebs, Z. Jin, R. Rudersdorf, A. L. Hughes, and D. H. O'Connor Unusually High Frequency MHC Class I Alleles in Mauritian Origin Cynomolgus Macaques J. Immunol., October 15, 2005; 175(8): 5230 - 5239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liang, D. R. Casimiro, W. A. Schleif, F. Wang, M.-E. Davies, Z.-Q. Zhang, T.-M. Fu, A. C. Finnefrock, L. Handt, M. P. Citron, et al. Vectored Gag and Env but Not Tat Show Efficacy against Simian-Human Immunodeficiency Virus 89.6P Challenge in Mamu-A*01-Negative Rhesus Monkeys J. Virol., October 1, 2005; 79(19): 12321 - 12331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Schmitz, R. P. Johnson, H. M. McClure, K. H. Manson, M. S. Wyand, M. J. Kuroda, M. A. Lifton, R. S. Khunkhun, K. J. McEvers, J. Gillis, et al. Effect of CD8+ Lymphocyte Depletion on Virus Containment after Simian Immunodeficiency Virus SIVmac251 Challenge of Live Attenuated SIVmac239{Delta}3-Vaccinated Rhesus Macaques J. Virol., July 1, 2005; 79(13): 8131 - 8141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Su, M. A. Luscher, Y. Xiong, T. Rustam, R. R. Amara, E. Rakasz, H. L. Robinson, and K. S. MacDonald Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques Int. Immunol., May 1, 2005; 17(5): 637 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Seaman, S. Santra, M. H. Newberg, V. Philippon, K. Manson, L. Xu, R. S. Gelman, D. Panicali, J. R. Mascola, G. J. Nabel, et al. Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys J. Virol., April 15, 2005; 79(8): 4580 - 4588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. Peyerl, H. S. Bazick, M. H. Newberg, D. H. Barouch, J. Sodroski, and N. L. Letvin Fitness Costs Limit Viral Escape from Cytotoxic T Lymphocytes at a Structurally Constrained Epitope J. Virol., December 15, 2004; 78(24): 13901 - 13910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Loffredo, J. Sidney, C. Wojewoda, E. Dodds, M. R. Reynolds, G. Napoe, B. R. Mothe, D. H. O'Connor, N. A. Wilson, D. I. Watkins, et al. Identification of Seventeen New Simian Immunodeficiency Virus-Derived CD8+ T Cell Epitopes Restricted by the High Frequency Molecule, Mamu-A*02, and Potential Escape from CTL Recognition J. Immunol., October 15, 2004; 173(8): 5064 - 5076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. de Groot, G. G. Doxiadis, N. G. de Groot, N. Otting, C. Heijmans, A. J. M. Rouweler, and R. E. Bontrop Genetic Makeup of the DR Region in Rhesus Macaques: Gene Content, Transcripts, and Pseudogenes J. Immunol., May 15, 2004; 172(10): 6152 - 6157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Muthukumar, A. Wozniakowski, M.-C. Gauduin, M. Paiardini, H. M. McClure, R. P. Johnson, G. Silvestri, and D. L. Sodora Elevated interleukin-7 levels not sufficient to maintain T-cell homeostasis during simian immunodeficiency virus-induced disease progression Blood, February 1, 2004; 103(3): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. O'Connor, B. R. Mothe, J. T. Weinfurter, S. Fuenger, W. M. Rehrauer, P. Jing, R. R. Rudersdorf, M. E. Liebl, K. Krebs, J. Vasquez, et al. Major Histocompatibility Complex Class I Alleles Associated with Slow Simian Immunodeficiency Virus Disease Progression Bind Epitopes Recognized by Dominant Acute-Phase Cytotoxic-T-Lymphocyte Responses J. Virol., August 15, 2003; 77(16): 9029 - 9040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhao, J. Pinczewski, V. R. Gomez-Roman, D. Venzon, V. S. Kalyanaraman, P. D. Markham, K. Aldrich, M. Moake, D. C. Montefiori, Y. Lou, et al. Improved Protection of Rhesus Macaques against Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge by a Replication-Competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag Recombinant Priming/gp120 Boosting Regimen J. Virol., August 1, 2003; 77(15): 8354 - 8365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. P. Lafont, A. Buckler-White, R. Plishka, C. Buckler, and M. A. Martin Characterization of Pig-Tailed Macaque Classical MHC Class I Genes: Implications for MHC Evolution and Antigen Presentation in Macaques J. Immunol., July 15, 2003; 171(2): 875 - 885. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1–3 domains (exons 2–4). Identity with Mamu-A*01 is
indicated with periods, while differences are given by the conventional
amino acid one-letter code. Lack of sequence information is indicated
by dashes. Novel alleles are indicated in bold.
